|Bid||0.0210 x N/A|
|Ask||0.0390 x 1200|
|Day's Range||0.0210 - 0.0440|
|52 Week Range||0.0210 - 0.0440|
|Beta (3Y Monthly)||1.65|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2019 - Nov 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
By John Vandermosten, CFA NASDAQ:PHIO READ THE FULL PHIO RESEARCH REPORT Phio Pharmaceuticals Corp. (NASDAQ:PHIO) reported second quarter 2019 results and filed its Form 10-Q on August 12, 2019. Since ...
Since the beginning of the year, the company has announced a new collaborations with Glycostem Therapeutics, the promotion of Dr. Gerrit Dispersyn to CEO and the appointment of Dr. John Barrett as CDO. Phio’s lead candidate, RXI-762, is pursuing immuno-oncology indications in collaboration with Center for Cancer Immune Therapy (CCIT) and Iovance Biotherapeutics. Development efforts are centered on reducing the immune checkpoints that appear on the surface of tumor infiltrating lymphocytes (TILs) in an approach that can be layered on to current manufacturing processes.
Phio Pharmaceuticals Corp. (PHIO) reported fourth quarter and full year results and filed its Form 10-K on March 27, 2018. Key operational events in 2018 include data presentations on NK cells, collaborations with Karolinska Institutet and Iovance Biotherapeutics and positive results from the Phase II assets. Other accomplishments include a change in the corporate name to Phio Pharmaceuticals, publication of sd-rxRNA immuno-oncology successes in Molecular Therapy and the elevation of Dr. Gerrit Dispersyn to Chief Executive Officer.
-Reflects Company's Transition to Develop Groundbreaking Immuno-Oncology Therapeutics- -Trading Under Nasdaq Symbol "PHIO" Begins Today, November 19- MARLBOROUGH, Mass. , Nov. 19, 2018 /PRNewswire/ ...